Entheias Biosciences is developing a novel therapeutic vaccine platform designed to restore immune control and achieve sustained viral suppression in patients with chronic HBV infection.
Learn moreChronic hepatitis B affects over 290 million people worldwide, with limited treatment options that rarely achieve functional cure. Current therapies suppress viral replication but do not eliminate the underlying infection.
Entheias Biosciences was founded to change this paradigm. We are developing a therapeutic vaccine platform designed to re-educate the immune system, enabling patients to achieve durable HBsAg loss and sustained immune control without lifelong antiviral therapy.
Despite decades of antiviral development, functional cure rates for chronic HBV remain below 10% with current standard of care. The field is converging on the consensus that a therapeutic vaccine — one that can restore T-cell and B-cell responses against HBV — is a critical missing piece.
Entheias is positioned at the forefront of this emerging space, with a differentiated approach grounded in deep immunological insight.
Our platform is designed to overcome the immune exhaustion characteristic of chronic HBV, reactivating both T-cell and B-cell responses against key viral antigens.
We focus on carefully selected HBV epitopes optimised to elicit broad, durable immune responses capable of driving HBsAg seroconversion.
Our therapeutic vaccine is designed to integrate with existing and emerging antiviral strategies, providing a complementary immunological mechanism for functional cure.
From the Greek for divinely inspired healing — a name that reflects our conviction that science, when driven by purpose, can achieve what was once thought impossible.
Entheias combines the Greek roots entheos (divinely inspired) and iasis (the act of healing), with a classical proper name ending that evokes the great healers of antiquity.
We are actively seeking partnerships with pharmaceutical companies to advance our therapeutic vaccine platform toward clinical development. We welcome conversations with BD, licensing, and R&D teams.
contact@entheiasbiosciences.com